Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden · Delayed Price · Currency is SEK 6.50
+0.24 (3.83%)
Nov 4, 2026, 9:00 AM CET
STO:ANNX Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 14.44 | 27.4 | 16.34 | 21.42 | 31.11 | 49.48 |
Cash & Short-Term Investments | 14.44 | 27.4 | 16.34 | 21.42 | 31.11 | 49.48 |
Cash Growth | -60.85% | 67.69% | -23.71% | -31.17% | -37.12% | 172.88% |
Other Receivables | 0.82 | 0.38 | 0.42 | 2.63 | 1.86 | 1.02 |
Receivables | 0.82 | 0.38 | 0.42 | 2.63 | 1.86 | 1.02 |
Prepaid Expenses | - | 0.79 | 0.63 | 0.87 | 0.67 | 0.22 |
Other Current Assets | 0.78 | - | - | - | - | - |
Total Current Assets | 16.04 | 28.57 | 17.38 | 24.92 | 33.65 | 50.72 |
Property, Plant & Equipment | 1.05 | 1.12 | 1.08 | 1.17 | 1.26 | 1.35 |
Long-Term Investments | 0.49 | 0.31 | 0.31 | 0.31 | 0.41 | 0.15 |
Other Intangible Assets | 0.09 | 0.16 | 0.27 | 0.37 | 0.47 | 0.58 |
Other Long-Term Assets | 0 | - | - | - | 0.89 | - |
Total Assets | 17.66 | 30.16 | 19.04 | 26.76 | 36.68 | 52.79 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.86 | 2.97 | 2.96 | 4.33 | 3.33 | 3.51 |
Accrued Expenses | 3.1 | 1.93 | 1.98 | 3.3 | 2.43 | 1.7 |
Other Current Liabilities | 0.36 | 0.33 | 0.39 | 0.32 | 0.77 | 0.84 |
Total Current Liabilities | 5.33 | 5.22 | 5.32 | 7.95 | 6.53 | 6.06 |
Other Long-Term Liabilities | 0 | - | - | - | - | - |
Total Liabilities | 5.33 | 5.22 | 5.32 | 7.95 | 6.53 | 6.06 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 14.43 | 11.68 | 8.82 | 5.74 | 2.56 | 27.45 |
Additional Paid-In Capital | 402.82 | 386.61 | 341.36 | 299.29 | 269.63 | 220.91 |
Retained Earnings | -404.92 | -373.36 | -336.46 | -286.21 | -242.16 | -201.63 |
Comprehensive Income & Other | - | - | - | - | 0.12 | - |
Shareholders' Equity | 12.33 | 24.93 | 13.71 | 18.81 | 30.15 | 46.73 |
Total Liabilities & Equity | 17.66 | 30.16 | 19.04 | 26.76 | 36.68 | 52.79 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 14.44 | 27.4 | 16.34 | 21.42 | 31.11 | 49.48 |
Net Cash Growth | -60.85% | 67.69% | -23.71% | -31.17% | -37.12% | 172.88% |
Net Cash Per Share | 1.95 | 4.14 | 3.61 | 12.82 | 21.27 | 60.31 |
Filing Date Shares Outstanding | 8.72 | 7.06 | 5.33 | 3.47 | 1.54 | 1.37 |
Total Common Shares Outstanding | 8.72 | 7.06 | 5.33 | 3.47 | 1.54 | 1.37 |
Working Capital | 10.71 | 23.34 | 12.06 | 16.97 | 27.12 | 44.66 |
Book Value Per Share | 1.41 | 3.53 | 2.57 | 5.43 | 19.52 | 34.05 |
Tangible Book Value | 12.24 | 24.77 | 13.45 | 18.44 | 29.68 | 46.15 |
Tangible Book Value Per Share | 1.40 | 3.51 | 2.52 | 5.32 | 19.21 | 33.63 |